Holen Sie sich die Stockscreener-App
18.55
0.38%
0.07
Vorhandelsmarkt:
18.30
-0.25
-1.35%
Schlusskurs vom Vortag:
$18.48
Offen:
$18.51
24-Stunden-Volumen:
2.17M
Relative Volume:
1.31
Marktkapitalisierung:
$1.64B
Einnahmen:
$217.42M
Nettoeinkommen (Verlust:
$-243.25M
KGV:
-6.6364
EPS:
-2.7952
Netto-Cashflow:
$-278.35M
1W Leistung:
+4.86%
1M Leistung:
-8.30%
6M Leistung:
-10.47%
1J Leistung:
+85.69%
1-Tages-Spanne:
$18.25
$18.62
1-Wochen-Bereich:
$17.31
$18.62
52-Wochen-Spanne:
$8.585
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
Firmenname
Syndax Pharmaceuticals Inc
Sektor
Branche
Telefon
781-419-1400
Adresse
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
18.55 | 1.64B | 217.42M | -243.25M | -278.35M | -2.7952 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-16 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-09-10 | Fortgesetzt | Stifel | Buy |
| 2025-09-04 | Fortgesetzt | Guggenheim | Buy |
| 2025-08-05 | Bestätigt | BTIG Research | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-06-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-31 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-10-25 | Eingeleitet | BofA Securities | Buy |
| 2023-10-11 | Eingeleitet | Goldman | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-07-11 | Eingeleitet | Guggenheim | Buy |
| 2023-04-17 | Fortgesetzt | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2023-01-03 | Eingeleitet | JP Morgan | Overweight |
| 2022-07-28 | Fortgesetzt | B. Riley Securities | Buy |
| 2022-04-11 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-15 | Eingeleitet | Goldman | Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Outperform |
| 2021-05-25 | Eingeleitet | Citigroup | Buy |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-05-22 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-22 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-05-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-04 | Eingeleitet | Barclays | Overweight |
| 2020-01-13 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-01-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2018-01-05 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | Eingeleitet | FBR & Co. | Outperform |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2016-10-07 | Eingeleitet | Guggenheim | Buy |
| 2016-03-28 | Eingeleitet | Citigroup | Buy |
| 2016-03-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-03-28 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Syndax Pharmaceuticals Inc Aktie (SNDX) Neueste Nachrichten
Syndax Pharmaceuticals Inc at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus
Syndax Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Eventide Asset Management LLC Has $26.01 Million Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (SNDX) Is Up 5.2% After Strong All-Oral Revuforj SAVE Trial DataWhat's Changed - Yahoo Finance
Voss Capital LP Buys Shares of 125,000 Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Rhenman & Partners Asset Management AB Sells 87,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
SNDX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $40 - GuruFocus
Syndax (SNDX) CMO sells 65,515 shares, retains 60,885 and large options - Stock Titan
SNDX (NASDAQ) Rule 144 notice: Director-linked sale of 31,235 shares - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
SNDX Stock Price, Quote & Chart - ChartMill
[144] Syndax Pharmaceuticals Inc SEC Filing - Stock Titan
Syndax showcases revuforj (revumenib) data at EHA 2026 - grafa.com
Syndax (SNDX) Reveals Encouraging Results from SAVE Trial for AM - GuruFocus
Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced (NASDAQ:SNDX) - Seeking Alpha
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026 - The Manila Times
Leukemia drug revumenib shows up to 97% remission in EHA 2026 data - Stock Titan
Syndax Pharmaceuticals Announces Publication of Save Data on Revuforj in Combination with Decitabine/Cedazuridine and Venetoclax in Relapsed/Refractory NPM1m, KMT2Ar, and NUP98r AML - marketscreener.com
SNDX6417984 Bond Coupon Analysis — Rate & Payments - TradingView
Syndax Pharmaceuticals (NASDAQ: SNDX) issues $250M 2.25% convertible notes due 2031 - Stock Titan
Syndax (NASDAQ: SNDX) investors back 2026 equity plan and new ESPP - Stock Titan
Syndax Pharmaceuticals, Inc. Bonds — Corporate Bond Rates - TradingView
Syndax Pharmaceuticals Inc Bonds — Corporate Bond Rates - TradingView
Syndax Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:SNDX) - MarketBeat
SNDX6417984 Bond Analysis — Key Metrics - TradingView
Transcript : Syndax Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-08-2026 02 - marketscreener.com
SNDX: Revuforj's clinical success and expanding pipeline drive growth, with new capital fueling future innovation - TradingView
Syndax Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
SNDX6417984 Bond Price and Chart — FINRA:SNDX6417984 - TradingView
Price-Driven Insight from (SNDX) for Rule-Based Strategy - Stock Traders Daily
A Look At Syndax Pharmaceuticals (SNDX) Valuation After Recent Share Price Weakness - Sahm
Syndax Pharmaceuticals prices $250M senior convertible notes - MSN
Syndax Pharmaceuticals prices $250 million convertible notes By Investing.com - Investing.com Australia
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Syndax (SNDX) Launches $250M Convertible Senior Note Offering - GuruFocus
Syndax Pharmaceuticals (SNDX) Faces Selling Pressure, Testing Near-Term Support LevelsLiquidity Order Flow - newsline.com
Syndax Pharmaceuticals prices $250 million convertible notes - Investing.com UK
Goldman Sachs Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $34 - Moomoo
Syndax Pharmaceuticals Prices $250 Million Convertible Senior Notes - TipRanks
Syndax Prices $250 Million 2.25% Convertible Notes Due 2031 in Private Placement - TradingView
Syndax (NASDAQ: SNDX) raises $250M via 2.25% convertible notes due 2031 - Stock Titan
Syndax Pharmaceuticals Announces $250 Million Private Placement of Convertible Senior Notes - Quiver Quantitative
Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes - The Manila Times
Syndax lines up $250M in 2.25% debt swappable into its stock - Stock Titan
H.C. Wainwright reiterates Syndax Pharmaceuticals stock rating on ASCO data - Investing.com Canada
Stifel reiterates Syndax Pharmaceuticals stock rating on ASCO data By Investing.com - Investing.com Canada
Syndax (SNDX) CFO sells 1,177 shares to cover RSU tax withholding - Stock Titan
Syndax Pharmaceuticals (SNDX) CEO sells shares to cover tax obligations - Stock Titan
Syndax Highlights Revuforj® (revumenib) Data Presented at ASCO 2026, Including an Oral Presentation of Post-Transplant Data - The Manila Times
Small leukemia study finds 90% 2-year survival with revumenib after transplant - Stock Titan
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026 - The Manila Times
Finanzdaten der Syndax Pharmaceuticals Inc-Aktie (SNDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Syndax Pharmaceuticals Inc-Aktie (SNDX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Botwood Nicholas A.J. | Head of R&D, CMO |
Jun 11 '26 |
Option Exercise |
13.82 |
22,515 |
311,157 |
95,165 |
| Botwood Nicholas A.J. | Head of R&D, CMO |
Jun 11 '26 |
Sale |
18.00 |
34,280 |
617,040 |
60,885 |
| Botwood Nicholas A.J. | Head of R&D, CMO |
Jun 12 '26 |
Sale |
18.14 |
31,235 |
566,603 |
60,885 |
1.27%
1.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):